-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Crohn's disease (CD) is a non-specific inflammatory bowel disease, mainly manifested in chronic relapse inflammation in the gastrointestinal tract and many other manifestations and complications.
proper classification of diseases is essential for individualized treatment of CD patients, and while the Montreal classification remains the most widely used classification, the importance of this traditional classification has recently been called into question.
more in-depth esolytic studies have shown that genetic and microbial esogens are layered differently based on the absence or presence of colons.
study aims to explore the relationship between this colon-based classification and clinical outcomes in CD patients compared to the Montreal classification.
conducted a retrospective clinical study of CD patients from a third-level referral center.
the Montreal classification, patients are classified as colon-related and non-colon-related diseases.
compared the clinical demographic data of the two categories, the differences between drugs and surgery.
main outcome is the need for large abdominal surgery.
in 934 patients, the middle age of colon-affected patients was earlier (23.0 (17.0-30.0) years vs 26.0 (19.0-35.0) years old, p s 0.001), and the frequency of lesions was higher (31.2%vs 1) 4.5 percent p .lt;0.001), intestinal performance was also more frequent (21.8% VS 14.5%, p s 0.010), but the narrow occurrence rate (B2) of colon-type CD (16.3% VS 24.0%, p s 0.005) was lower than in non-colitis patients.
colon-related diseases are protective factors for large abdominal surgery (risk ratio, 0.689; 95% confidence interval (CI), 0.481-0.985; p s 0.041).
, however, patients with CD with colon disease are more likely to develop steroids (ratio (OR) of 1.793; 95% CI, 1.206-2.666; p s 0.004) and thiopental / 6- aquinine (AZA / 6-MP) therapy (OR, 1.732); 95% CI, 1.103-2.719; p . . . 0.017).
classification cannot predict surgical or steroid hormones and treatment needs for AZA/6-MP.
study supports the rationale for colon-based classification of diseases.
the new CD classification is better at predicting clinical outcomes than the Montreal classification.
。